Clinical implications of chemotherapeutic agent organ toxicity on perioperative care

Zeien, Justin; Qiu, Wendy; Triay, Mason; Dhaibar, Hemangini A.; Cruz‐Topete, Diana; Cornett, Elyse M.; Urits, Ivan; Viswanath, Omar; Kaye, Alan D.

doi:10.1016/j.biopha.2021.112503

Cited by 33 publications

(14 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to the previous studies ( 21 , 22 ), there was a significant reduction in neutrophil count among BC patients who completed the 3 rd cycle of AC chemotherapy treatment. According to previous studies, neutropenia is the most common toxicity seen in patients undergoing systemic AC chemotherapy treatment ( 26 – 28 ). The reduction of neutrophils in this study could attribute to impairment in hematopoiesis.…”

Section: Discussionmentioning

confidence: 99%

Effects of Adriamycin-Cytoxan chemotherapy on hematological and electrolyte parameters among breast cancer patients

Tadesse

Leminie

2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundAdriamycin-Cytoxan (AC) is a common chemotherapy treatment for breast cancer (BC) patients. Its electrolyte and hematological adverse effects have not been addressed adequately.ObjectiveThis study aimed to assess the effect of AC on hematological and electrolyte parameters among BC patients.MethodsA hospital-based comparative cross-sectional study design was conducted from March to November 2022. Randomly selected AC-treated (n=100) and untreated (n=100) patients were included. Structured questionnaire and medical records were used to collect sociodemographic data. Anthropometric parameters, hematological indices, and serum electrolytes were measured. Cobas Integra 400+and SYSMEX-XT-4000i were used to analyze serum electrolytes and hematological indices respectively. The data were analyzed using SPSS version 25. Independent t-test and chi-square test were used. p-value <0.05 was considered statistically significant.ResultsAC-treated patients’ mean total white blood cell (TWBC), neutrophil (NE), lymphocyte (LY), red blood cell (RBC), hemoglobin (Hgb), hematocrit (HCT), and sodium(Na+) values were significantly reduced (p<0.05) than patients with no treatment. However, mean eosinophils (EO), platelet (PLT) counts, red cell distribution-width (RDW), potassium (K+), and plateletcrit (PCT values were significantly increased (p<0.05).ConclusionThe majority of blood cells and serum sodium were affected by AC treatment. Incorporating these parameters in the routine analysis and further studies on the detailed mechanism of action of this drug is required.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Adriamycin-Cytoxan chemotherapy on hematological and electrolyte parameters among breast cancer patients

Tadesse

Leminie

2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…However, chemotherapeutic agents affect both cancer and healthy cells (Senapati et al, 2018). These adverse effects are among the leading causes of a high mortality rate in patients (Zeien et al, 2022). Additionally, due to poor drug bio‐accessibility, high doses of chemotherapeutic agents should be applied, leading to increased toxicity.…”

Section: Introductionmentioning

confidence: 99%

Chitosan‐coated nanoparticles in innovative cancer bio‐medicine

Rezaei,

Zarkesh,

Fotouhi

et al. 2024

Drug Development Research

View full text Add to dashboard Cite

In the recent decade, nanoparticles (NPs) have had enormous implications in cancer biomedicine, including research, diagnosis, and therapy. However, their broad application still faces obstacles due to some practical limitations and requires further development. Recently, there has been more interest in the coated class of nanoparticles to address those challenges. Chitosan‐coated NPs are simple to produce, biodegradable, biocompatible, exhibit antibacterial activity, and have less cytotoxicity. This study provides an updated and comprehensive overview of the application of chitosan‐coated NPs as a promising class of NPs in cancer biomedicine. Additionally, we discussed chitosan‐coated lipid, metal, and polymer‐based nanoparticles in biomedical applications. Furthermore, different coating methods and production/characterization procedures were reviewed. Moreover, the biological and physicochemical advantages of chitosan‐coated NPs, including facilitated controlled release, greater physicochemical stability, improved cell/tissue interaction, and enhanced bioavailability of medications, were highlighted. Finally, the prospects of chitosan‐coated NPs in cancer biomedicine were discussed.

show abstract

“…Indeed, the clinical spectrum of toxicities is vast, ranging from less severe toxicities, such as nausea, vomiting, dysgeusia, and hair loss, to those that are more serious and potentially life-threatening including myelosuppression, febrile neutropenia, severe oral mucositis, and sepsis [2,3]. In addition to these acute toxicities, several late effects are associated with chemotherapy, involving the cardiac [4,5], neurological [6], renal [7], pulmonary [8], and hepatic systems [9]. Estimates indicate that more than a quarter of patients receiving conventional chemotherapy experience severe (grade IV) potentially life-threatening toxicities [10].…”

Section: Introductionmentioning

confidence: 99%

New light on chemotherapy toxicity and its prevention

Juthani,

Punatar,

Mittra

2024

BJC Rep

View full text Add to dashboard Cite

Most patients with cancer receive chemotherapy. Unfortunately, chemotherapy is associated with a number of potentially life-threatening side effects. There is a need to ameliorate chemotoxicity to improve therapeutic outcomes and quality of life. Chemotoxicity arises from systemic DNA damage and inflammation in healthy cells due to chemotherapy drugs. Traditionally, these processes are believed to be caused by the direct death of normal cells by chemotherapeutic drugs. However, new research has challenged this dogma by suggesting that chemotoxicity is a secondary effect associated with the release of cell-free chromatin particles (cfChPs) from cells subjected to drug-induced death. Released cfChPs can freely enter into bystander healthy cells to inflict double-strand (dsDNA) breaks and activate inflammatory and apoptotic pathways. The drug-induced cell death and cfChPs release have cascading effects that exaggerate and prolong chemotoxicity. Furthermore, evidence has emerged from laboratory and preclinical studies, and two phase II clinical trials, indicating that chemotoxicity can be minimised by deactivating cfChPs. Three cfChPs-deactivating agents have been identified, of which the nutraceutical combination resveratrol and copper (R–Cu)—easily administered orally and with little toxicity—is the agent of choice for human therapeutic use. This article aims to provide practising medical oncologists with a perspective on this emerging research on chemotoxicity and its prevention and its potential implications for the future. Well-designed randomised clinical trials will be necessary to establish the true clinical value of these findings in day-to-day practice.

show abstract

Clinical implications of chemotherapeutic agent organ toxicity on perioperative care

Cited by 33 publications

References 42 publications

Effects of Adriamycin-Cytoxan chemotherapy on hematological and electrolyte parameters among breast cancer patients

Effects of Adriamycin-Cytoxan chemotherapy on hematological and electrolyte parameters among breast cancer patients

Chitosan‐coated nanoparticles in innovative cancer bio‐medicine

New light on chemotherapy toxicity and its prevention

Contact Info

Product

Resources

About